Nucleic acid amplification technique for detection of Chlamydia trachomatis infection from clinical urogenital swabs
Language English Country United States Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
18062194
DOI
10.1007/bf02932100
Knihovny.cz E-resources
- MeSH
- Chlamydia trachomatis genetics isolation & purification MeSH
- Chlamydia Infections diagnosis epidemiology microbiology MeSH
- DNA, Bacterial chemistry genetics MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Male Urogenital Diseases diagnosis epidemiology microbiology MeSH
- Plasmids chemistry genetics MeSH
- Polymerase Chain Reaction methods MeSH
- Sequence Analysis, DNA MeSH
- Aged MeSH
- Sensitivity and Specificity MeSH
- Female Urogenital Diseases diagnosis epidemiology microbiology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Geographicals
- Slovakia epidemiology MeSH
- Names of Substances
- DNA, Bacterial MeSH
An improved nucleic acid amplification test (NAAT) to detect Chlamydia trachomatis infections, based on PCR amplification within its cryptic plasmid (CT1/CT2 Test) was developed. DNA was extracted from urogenital swabs and a 594-bp long DNA fragment from the cryptic plasmid (pCT) was amplified. The sensitivity and specificity of the CT1/CT2 Test were determined to be 100 and 99%, respectively, when directly compared with current amplification kit for sexually transmitted diseases (MPCR). Basic epidemiological data related to the patients attending gynecological and/or urological clinics are also provided. The overall prevalence rate in this group of patients suspected for C. trachomatis infection was determined to be about 95 per 1000 (88 and 107 per 1000 in females and males, respectively). It demonstrates that the CT1/CT2 Test is suitable for epidemiological screening and/or diagnostic practice.
See more in PubMed
Sex Transm Dis. 1992 Jul-Aug;19(4):185-92 PubMed
Public Health. 2007 Jul;121(7):534-9 PubMed
Sex Transm Dis. 2007 Aug;34(8):570-3 PubMed
J Gen Microbiol. 1993 May;139(5):1083-92 PubMed
Plasmid. 1990 Mar;23(2):144-8 PubMed
Plasmid. 1990 Mar;23(2):149-54 PubMed
Sex Transm Dis. 2003 Jan;30(1):64-70 PubMed
Infect Immun. 1998 Dec;66(12):6010-3 PubMed
Microbiol Immunol. 2000;44(4):267-9 PubMed
J Community Health. 2004 Aug;29(4):265-9 PubMed
Plasmid. 1992 May;27(3):231-6 PubMed
JAMA. 1991 Nov 13;266(18):2587-93 PubMed
Microbiology (Reading). 1997 Jun;143 ( Pt 6):1847-1854 PubMed
Ann Intern Med. 2003 Aug 5;139(3):178-85 PubMed
Sex Transm Infect. 2004 Apr;80(2):121-3 PubMed
Infect Immun. 1997 Jul;65(7):2965-9 PubMed
Comput Biol Med. 2000 May;30(3):127-34 PubMed
J Adolesc Health. 2003 May;32(5):336-9 PubMed
Plasmid. 1992 Nov;28(3):247-57 PubMed
J Infect. 1992 Jul;25 Suppl 1:35-7 PubMed
J Clin Microbiol. 2004 Jul;42(7):3041-5 PubMed
Diagn Microbiol Infect Dis. 1997 Jun;28(2):75-9 PubMed
Clin Microbiol Infect. 2003 Mar;9(3):194-201 PubMed
J Clin Microbiol. 1992 Nov;30(11):2814-21 PubMed
J Clin Microbiol. 2000 Mar;38(3):1085-93 PubMed
Int J STD AIDS. 2007 Feb;18(2):89-92 PubMed
Plasmid. 1986 Jul;16(1):52-62 PubMed
Sex Transm Dis. 2004 Jul;31(7):409-14 PubMed
J Histochem Cytochem. 1998 Sep;46(9):1017-23 PubMed
Plasmid. 1987 Nov;18(3):205-14 PubMed
Health Technol Assess. 2007 Mar;11(8):iii-iv, ix-xii, 1-165 PubMed
